| 000 | 01903 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515035840.0 | ||
| 264 | 0 | _c20060929 | |
| 008 | 200609s 0 0 eng d | ||
| 022 | _a1744-7682 | ||
| 024 | 7 |
_a10.1517/14712598.6.9.891 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVonk, Alieke G | |
| 245 | 0 | 0 |
_aHost defence against disseminated Candida albicans infection and implications for antifungal immunotherapy. _h[electronic resource] |
| 260 |
_bExpert opinion on biological therapy _cSep 2006 |
||
| 300 |
_a891-903 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xeconomics |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntifungal Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aCandida albicans _ximmunology |
| 650 | 0 | 4 |
_aCandidiasis _xdrug therapy |
| 650 | 0 | 4 |
_aComplement System Proteins _ximmunology |
| 650 | 0 | 4 |
_aDendritic Cells _ximmunology |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aFluconazole _xtherapeutic use |
| 650 | 0 | 4 |
_aFungal Vaccines _xadministration & dosage |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunity, Cellular _xdrug effects |
| 650 | 0 | 4 |
_aImmunity, Innate _xdrug effects |
| 650 | 0 | 4 |
_aInterferon-gamma _xtherapeutic use |
| 650 | 0 | 4 |
_aKiller Cells, Natural _ximmunology |
| 650 | 0 | 4 |
_aPhagocytes _ximmunology |
| 650 | 0 | 4 |
_aRandomized Controlled Trials as Topic _xeconomics |
| 650 | 0 | 4 |
_aReceptors, Pattern Recognition _ximmunology |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 |
_aTh1 Cells _ximmunology |
| 650 | 0 | 4 |
_aTh2 Cells _ximmunology |
| 700 | 1 | _aNetea, Mihai G | |
| 700 | 1 | _avan der Meer, Jos W M | |
| 700 | 1 | _aKullberg, Bart Jan | |
| 773 | 0 |
_tExpert opinion on biological therapy _gvol. 6 _gno. 9 _gp. 891-903 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/14712598.6.9.891 _zAvailable from publisher's website |
| 999 |
_c16504849 _d16504849 |
||